Shanghai IxCell Biotech Co., Ltd. is a biotechnology company specializing in cell-based pharmaceuticals, with advanced capabilities in large-scale manufacturing for cell therapies. Our mission, "Dedicated to unmatched excellence in the advancement of cell-based pharmaceuticals," drives us to develop a robust product pipeline in three primary areas: mesenchymal stem cell therapies, induced pluripotent stem cell therapies, and immune cell therapies, all supported by a state-of-the-art manufacturing platform. Our clinical pipeline targets a range of diseases, including knee osteoarthritis, stroke, pulmonary fibrosis, autoimmune disorders, and solid tumors. Through independent research and continuous innovation, we have secured over forty patents for cell therapy inventions and set industry-leading manufacturing standards. Our 4,000-square-meter facility in the Zhangjiang Core Park of Pudong, Shanghai, integrates research, development, and production, allowing for seamless transition from discovery to commercialization.